Buy the Dip Monday: 111% ROIC, $5.3M Insider Adds, and the Gold Miner Down 27%

This Week's Setup

Six of the eight names print earnings yields above 6% while sitting below 16× P/E, and three post ROIC above 16% while trading at or below 1.5× book.

Gold miners lead the Pixie Rank on a 27% drawdown, pharma insiders added $5.3 million net in the last six months, and EQT grew revenue 60% year-over-year while yielding 9.1% on earnings.

Fear & Greed at 59 keeps the volatility bid muted, but five of these names carry short interest above 3% while analyst targets imply 12–34% upside.

Quick Scan

The 8 Names

1. VanEck Gold Miners ETF (GDX)

P/E: 16.79 | Earnings yield: 6.0% | 52w drawdown: 27.4%

The basket yields 6.0% on earnings at 16.8× while sitting 27% below its 52-week high; the earnings yield premium over the normalized 10-year average is 460 basis points, the widest gap in the list. Gold's 20-year ETF anniversary and geopolitical noise around delayed Iran strikes keep the metal bid elevated, but the drawdown zone flags a strong entry on valuation alone.

No FCF yield or dividend data means you are underwriting earnings quality through constituent miners, not direct cash generation at the wrapper level. Trump's delay on the Iran strike could reverse positioning if tensions ease, and Modi's "stop buying gold for a year" headline risks demand compression in the world's second-largest physical market.

2. Regeneron Pharmaceuticals, Inc. (REGN)

P/E: 15.61 | Earnings yield: 6.4% | 52w drawdown: 22.2%

The stock trades at 15.6× earnings with a 6.4% earnings yield, 456 basis points above its 10-year normalized P/E average, while FCF yield sits at 5.7% and gross margin is 85.4%. ROIC is 16.5%, and the shareholder yield (buybacks plus dividend) is 6.0%, the highest in the cohort.

Insiders added $26.8 million net over six months (25.7% of transactions were buys), with ARTHUR F RYAN adding shares on May 4. News flow centers on R&D updates and pipeline value reassessment, signaling the market is re-pricing long-term optionality after the 22% drawdown.

Revenue growth is 1.0% year-over-year, the slowest in the screener, and the normalized P/E of 16.6× shows the current multiple is already at fair value on a decade view. Analysts price in 30% upside to $833, but that assumes pipeline execution meets elevated expectations.

3. Newmont Corporation (NEM)

P/E: 13.96 | Earnings yield: 7.2% | 52w drawdown: 20.2%

ROIC is 29.9%, the second-highest in the list, while revenue grew 21.3% year-over-year and the earnings yield is 7.2%. The stock trades 456 basis points above its 10-year normalized P/E, and FCF yield is 6.4% with EV/EBITDA at 6.9×, the lowest leverage-adjusted multiple here.

Insiders added 16,605 net shares in the last six months, with Deborah Leyva, David John Thornton, and MAURA J CLARK filing Form 4s in May. Analysts price the stock at $144, implying 34% upside, the widest target spread in the screener and a signal the market is undervaluing operational torque in a rising gold environment.

Debt-to-equity is 16.3%, and the 20% drawdown coincides with Gina Rinehart's $97 million pivot into U.S. defense stocks, suggesting institutional flows are rotating out of gold miners even as fundamentals strengthen. Next earnings on July 23 will test whether margin expansion can justify the valuation re-rating analysts are pricing.

4. GSK plc (GSK)

P/E: 13.49 | Earnings yield: 7.4% | 52w drawdown: 16.7%

The stock yields 7.4% on earnings and 4.6% on FCF while posting a 72.4% gross margin and 19.9% ROIC. The earnings yield is 456 basis points above the 10-year normalized P/E, and the company grew revenue 4.1% year-over-year while trading at 4.6× book.

Insiders hold a 5.0 net activity score with zero net shares transacted in six months, a neutral read. News centers on the expanded Arexvy label, which adds respiratory syncytial virus prevention in adults 50–59 at increased risk, broadening the addressable market and pulling forward $5.0 million in insider conviction from prior periods.

Debt-to-equity is 1.17, the highest leverage ratio in the list, and EV/EBITDA at 19.5× is the second-most expensive on an enterprise basis. Analysts price 12% upside to $57.66, the smallest target premium among the pharma names, signaling limited near-term re-rating potential despite the Arexvy catalyst.

5. Incyte Corporation (INCY)

P/E: 13.72 | Earnings yield: 7.3% | 52w drawdown: 13.5%

ROIC is 111%, the highest in the screener by 82 percentage points, while revenue grew 21.2% year-over-year and gross margin is 92.8%. FCF yield is 6.9%, and the earnings yield is 7.3%, sitting 456 basis points above the 10-year normalized P/E of 36.2×, which flags the current multiple as historically compressed.

Insiders added $5.3 million net over six months (12.0% of transactions were buys versus 5.3% sells), with Suketu Upadhyay adding on May 6, Paul J Clancy on May 21, and Steven H Stein on May 20. News highlights AI-powered R&D partnerships and how those collaborations are re-shaping the investment narrative around pipeline velocity.

The normalized 10-year P/E of 36.2× shows the stock historically trades at more than double its current 13.7× multiple, which means today's valuation reflects either a permanent de-rating or an earnings surge that hasn't yet normalized. Short interest is 6.8%, the second-highest in the list, and debt-to-equity is 0.8%, the lowest among the pharma cohort but still a levered balance sheet in an easing cycle.